Kintara Therapeutics, Inc.

NasdaqCM:KTRA Stock Report

Market Cap: US$12.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Kintara Therapeutics Management

Management criteria checks 3/4

Kintara Therapeutics' CEO is Robert Hoffman, appointed in Nov 2021, has a tenure of 2.92 years. total yearly compensation is $1.18M, comprised of 65.5% salary and 34.5% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $14.92K. The average tenure of the management team and the board of directors is 4.2 years and 4.3 years respectively.

Key information

Robert Hoffman

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage65.47%
CEO tenure2.9yrs
CEO ownership0.1%
Management average tenure4.2yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 19

Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial

Kintara Therapeutics (NASDAQ:KTRA) said it paused its REM-001 program in cutaneous metastatic breast cancer (CMBC) to save cash. The money will be used to fund an ongoing international registrational study of VAL-083 to treat a type of brain cancer called glioblastoma (GBM), the company said in a statement on Wednesday. Kintara President and CEO Robert Hoffman expects results from the GBM AGILE study of VAL-083 at the end of 2023. By pausing the REM-001 program, Kintara expects to save ~$3M through 2023. "We will continue to explore ways to restart REM-001, including use of grants from applications currently under review to support the funding of the planned 15-patient CMBC study. Although this was a difficult decision, we believe saving approximately $3.0 million through calendar year 2023 is prudent given the current capital market conditions," said Hoffman. KTRA +65.73% to $0.17 premarket Oct. 19
Seeking Alpha • Sep 27

Kintara Therapeutics GAAP EPS of -$0.52

Kintara Therapeutics press release (NASDAQ:KTRA): FY GAAP EPS of -$0.52. At June 30, 2022, Kintara had cash and cash equivalents of approximately $11.8 million.
Seeking Alpha • Aug 03

Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund

Kintara Therapeutics (NASDAQ:KTRA) stated Wednesday it has signed a direct equity purchase agreement for up to $20M investment with a Chicago-based institutional investor- Lincoln Park Capital Fund. Under the deal, Kintara will have the right, but not the obligation, to sell to LPC up to $20M of its shares over the period of 3-year agreement term. The company expects this commitment from LPC will provide financial flexibility and is aligned with Kintara's long-term strategy for value creation. KTRA shares jump 64% in pre-market, Wednesday.  Kintara said it intends to use net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 and REM-001.
Analysis Article • Apr 12

Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Robert Hoffman's remuneration changed compared to Kintara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024US$1mUS$775k

-US$9m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023n/an/a

-US$11m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023US$1mUS$590k

-US$15m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022n/an/a

-US$19m

Sep 30 2022n/an/a

-US$22m

Jun 30 2022US$3mUS$357k

-US$25m

Mar 31 2022n/an/a

-US$26m

Dec 31 2021n/an/a

-US$28m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021US$270kn/a

-US$42m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020n/an/a

-US$34m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020US$113kn/a

-US$9m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019n/an/a

-US$8m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019US$70kn/a

-US$8m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018n/an/a

-US$9m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018US$151kn/a

-US$11m

Compensation vs Market: Robert's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD661.20K).

Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.

CEO

Robert Hoffman (58 yo)

2.9yrs
Tenure
US$1,183,060
Compensation

Mr. Robert E. Hoffman, BBA, CPA, serves as an Independent Director at FibroBiologics, Inc. (Formerly, FibroBiologics LLC) since April 2021. He had been Independent Director of Antibe Therapeutics Inc. sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Hoffman
President2.9yrsUS$1.18m0.12%
$ 14.9k
Jeffrey Bacha
Founder14.8yrsno datano data
Greg Johnson
Acting Head of Operations4.2yrsno datano data
4.2yrs
Average Tenure

Experienced Management: KTRA's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Hoffman
President6.5yrsUS$1.18m0.12%
$ 14.9k
Tamara Favorito
Independent Director3.5yrsUS$94.56k0%
$ 0
Robert Toth
Independent Director11.2yrsUS$92.06k0.000060%
$ 7.7
Mario Lacouture
Member of Scientific Advisory Board3.6yrsno datano data
Laura Johnson
Independent Director4.3yrsUS$91.06k0.00011%
$ 14.1
4.3yrs
Average Tenure
60.5yo
Average Age

Experienced Board: KTRA's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/17 23:05
End of Day Share Price 2024/10/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kintara Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group